Loading data for PRQR — first visit, this takes a few seconds.

Alerta

ProQR Therapeutics N.V. (PRQR)

NasdaqCM: PRQR · Precio en tiempo real · USD

2.27

+0.05 (2.25%)

Al cierre: Aug 20, 2026, 8:00 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

2.25% (1D)

No hay datos disponibles

Precio de compra	1.73
Capitalización de mercado	320.34M
Ingresos (TTM)	18.42M
Beneficio neto (TTM)	-42.04M
	0.03
	-0.46
	n/a
	-4.08
P/B (TTM)	5.50
P/S (TTM)	17.39
Fecha de resultados	Nov 5, 2026

Precio de venta	2.76
Volumen	2,654,707
Volumen medio (20D)	1,054,216
Abierto	2.35
Anterior Cerrar	2.22
Rango del día	2.14 - 2.44
Rango de 52 semanas	1.33 - 3.10
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de PRQR

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targe...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Sep 18, 2014

Empleados 186

Bolsa de Valores NasdaqCM

Símbolo bursátil PRQR

Sitio web https://www.proqr.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de ProQR Therapeutics fueron 15.91M, una disminución de -15.86% en comparación con 18.91M del año anterior. Las ganancias fueron -42.18M, un aumento de 51.94%.

Estados financieros

Sorpresa de resultados

ProQR Therapeutics ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $2.03M falla las estimaciones por $0, con -55.01% Disminución interanual.

EPS de -0.09 supera las estimaciones en 0.09, con 35.71% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que ProQR Therapeutics N.V. publique sus resultados el Nov 5, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 meses hace · Simply Wall St.

Undervalued Penny Stocks To Consider In June 2026

Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stoc...

3 meses hace · Simply Wall St.

ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%

Today is shaping up negative for ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders, with the analysts delivering a...

3 meses hace · Zacks

Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3 meses hace · Zacks

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 meses hace · Simply Wall St.

3 Promising Penny Stocks With Market Caps Up To $600M

The market has climbed 1.8% in the last 7 days and is up 30% over the past year, with earnings projected to grow by 16% annually. Penny stocks, while a somewhat outdated term, continue to represent in...

Página 1 de 2

ProQR Therapeutics N.V. (PRQR)